Please upgrade your browser.
IMBiotechnologies Receives FDA Clearance to Market Occlusin® 500 Biodegradable Microspheres in the U.S.
OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids.
A CME activity from Clinical Care Options
The rate of unintentionally discovered renal masses has been increasing along with a parallel increased incidence of renal cell carcinoma both in men and women.
According to the Uwajima Tokushukai Hospital, the couple had asked the hospital in February whether it was possible to transplant the kidney from the wife, who had kidney cancer, to the husband.
Slides from the Fifth European International Kidney Cancer Symposium, held May 7 & 8, in London, England, are available online. Also online are selected presentations from the First European Kidney Cancer Nursing Conference.
Fuhrman Grade Provides Higher Prognostic Accuracy Than Nucleolar Grade for Papillary Renal Cell Carcinoma
Each grading system performs well but the predictive accuracy of Fuhrman grade is statistically superior to that of nucleolar grade and only.
Plans are continuing for the June 4 and 5 yard sale at Edgecomb Town Hall, to benefit the Kidney Cancer Association.
Mylan Inc. (MYL) has applied for U.S. regulatory approval to sell a generic version of Pfizer Inc.'s (PFE) Sutent cancer pill by challenging several patents on the drug.
Its a nasty-looking chunk of cancer, a plug of renal cell carcinoma that sometimes finds its way into the inferior vena cava. Because of its location in the bodys largest vein and its potential threat to the heart and brain, this tumor thrombus is serious indeed.
Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism
Multi-targeted tyrosine kinase inhibitors (MTKIs) are the standard in the treatment of metastatic renal cell carcinoma (mRCC). In spite their clinical activity, interaction with physiological functions has been shown. Here, we report on alterations of the bone mineral metabolism in patients with mRCC treated with MTKIs.
|Powered by NeonCRM|